溶血栓药物研究进展  

The advances of Thrombolytics Drugs

作　　者：姚天赐[1] 许云禄[1] 

机构地区：[1]福建医科大学蛇毒研究所,福州350004

出　　处：《海峡药学》2010年第6期1-5,共5页Strait Pharmaceutical Journal

摘　　要：血栓性疾病如心肌梗死、动脉血栓和脑梗死等严重危害人类的身体健康,溶栓被认为是治疗血栓性疾病的重要方法之一。近年来溶栓药物的研发主要集中在两方面,一方面为通过基因工程和单克隆抗体技术改造的新型纤溶酶原激活剂药物,另一方面为新来源的溶栓药。本文将先概述溶栓机理,并对近年来溶栓药物的研究进展及发展方向进行综述。Thromboembolic diseases such as myocardial infarction,arterial embolism and cerebral infarction are Seriously endangering the health of human beings.Thrombolytic therapy play an important role in Thromboembolic diseases.In recent years,development of thrombolytic drugs mainly concentrated in two areas：New type of plasminogen activator drugs using genetic engineering or monoclonal antibody technology and new sources of thrombolytic drugs.In this paper,we will discuss the thrombolytic mechanism,and review the advances of the recent research abount thrombolytics drugs.

关 键 词：溶栓药物 纤溶酶原激活剂 血栓病 

分 类 号：R969[医药卫生—药理学] R969.4[医药卫生—药学]